Dr. Awad on Objectives of the Phase 2 GEOMETRY Mono-1 Study in NSCLC

Mark M. Awad, MD, PhD, clinical director of the Thoracic Oncology Treatment Center and physician at Dana-Farber Cancer Institute, and an assistant professor of medicine at Harvard Medical School, discusses the main objectives of the phase 2 GEOMETRY mono-1 study in patients with MET exon 14 skipping (METex14)-mutated non–small cell lung cancer (NSCLC).

The trial had several objectives, says Awad. Many mutations that can impact METex14 can be identified, and some of these mutations reside in the flanking introns, explains Awad. To this end, one of the main goals of the trial was to determine whether certain mutations correlated more with other co-mutations or genomic abnormalities, adds Awad. 

Additionally, investigators wanted to develop a better understanding of PD-L1 expression and tumor mutational burden in this molecular lung cancer subtype, says Awad.

By examining patients who had serial biopsies that underwent sequencing, investigators also set out to identify putative mechanisms of acquired resistance to MET kinase inhibitors, adds Awad. The hope is that a greater understanding of resistance mechanisms could inform the development of drugs that could potentially overcome or prevent resistance from emerging, concludes Awad.